Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications

The CIRROXABAN randomized controlled trial assessed rivaroxaban 10 mg daily against placebo in patients with cirrhosis complicated by portal hypertension and moderate liver dysfunction.
Rivaroxaban treatment showed a trend towards reduced portal hypertension-related complications or death/liver transplant, with a favorable effect particularly in patients with Child-Pugh B7 cirrhosis.
Non-portal hypertension-related bleeding events were more frequent in the rivaroxaban group, yet there was no significant increase in major bleeding.
These findings support further exploration of direct oral anticoagulants in cirrhosis to prevent decompensation, balancing efficacy and bleeding risk.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The CIRROXABAN randomized controlled trial assessed rivaroxaban 10 mg daily against placebo in patients with cirrhosis complicated by portal hypertension and moderate liver dysfunction.
Rivaroxaban treatment showed a trend towards reduced portal hypertension-related complications or death/liver transplant, with a favorable effect particularly in patients with Child-Pugh B7 cirrhosis.
Non-portal hypertension-related bleeding events were more frequent in the rivaroxaban group, yet there was no significant increase in major bleeding.
These findings support further exploration of direct oral anticoagulants in cirrhosis to prevent decompensation, balancing efficacy and bleeding risk.

Sign in free to continue reading